Made of Genes raises a capital increase of 3 million euros and launches a new product within the Covid-19 framework

The Catalan start-up Made of Genes, a company specialized in personalized health, has announced the closing of a Pre-Series A Capital increase of more than three million Euros dedicated to launch and promote its new product, Made of Genes #REACTIVATE. It is a highly innovative test that combines an integrative analysis of genetic, serological, and metabolic markers to deliver an integrated response to Covid-19.

After announcing a microfinance round with BHH member Capital Cell last November, Made of Genes has added other international funds in a round of more than €3,000,000, which was formalized during the state of alarm. This capital increase has been led by the Barcelona family office FCV Equity, with the participation of The Scale Lab Andorra fund, the London fund Break Off Capital as well as other investors already present in the company such as CG Health Ventures and the super-business angel Albert Armengol, CEO of Doctoralia.

Also, the company has added to its personalized health services catalogue Made of Genes #REACTIVATE, a comprehensive test that combines genetic, biochemical and serological analysis to give a global vision of the health status of its users after the lockdown.

The Made of Genes #REACTIVATE test combines genetic markers analysis with an IgG antibody test and biochemical analysis to find out if a given person has already suffered the disease, if they are immunized, if they can suffer major respiratory complications if case of being infected in the future, and how to reduce the risk of comorbidities in an exceptional healthcare setting. The price of this service is €95.

“With the money from the investment round in our bank account we had two options: stand idly by, waiting for the storm to pass by, or do the thing we know: to improve people’s health when is more necessary than ever,” says Dr. Oscar Flores, CEO at Made of Genes.  “It is an opportunistic product, and we know that; this is why we are offering it almost at cost price, since we don’t want this situation to earn money, but to increase the number of people accessing Personalized Health services, as something different from the traditional genetic testing”, he adds.